Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
32.64
-0.40 (-1.21%)
At close: May 08, 2025, 12:58 PM
-1.21% (1D)
| Bid | 32.61 |
| Market Cap | 3.9B |
| Revenue (ttm) | 18.47M |
| Net Income (ttm) | -589.53M |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -6.17 |
| Forward PE | -7.29 |
| Analyst | Buy |
| Ask | 32.68 |
| Volume | 1,028,677 |
| Avg. Volume (20D) | 2,153,055 |
| Open | 32.76 |
| Previous Close | 33.04 |
| Day's Range | 31.67 - 32.94 |
| 52-Week Range | 31.67 - 68.44 |
| Beta | 0.81 |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Cytokinetics has released their quartely earnings
on May 6, 2025:
6 days ago
-12.98%
Cytokinetics shares are trading lower after the co...
Unlock content with
Pro Subscription
5 days ago
+0.19%
Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.
